Opinion Review
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2019; 25(26): 3291-3298
Published online Jul 14, 2019. doi: 10.3748/wjg.v25.i26.3291
Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation
Jose Tiago Silva, Rafael San-Juan, Mario Fernández-Ruiz, José María Aguado
Jose Tiago Silva, Rafael San-Juan, Mario Fernández-Ruiz, José María Aguado, Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), School of Medicine, Universidad Complutense, Madrid 28041, Spain
Author contributions: Silva JT was responsible for the literature review and the drafting and writing of the manuscript; San-Juan R, Fernández-Ruiz M and Aguado JM contributed to the editing, critical revision and approval of the final version.
Supported by “Plan Nacional de I+D+I”; Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias [FIS] PI14/00174), Subdirección General de Redes y Centros de Investigació n Cooperativa, Spanish Ministry of Science, Innovation and Universities, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016); and was cofinanced by the European Development Regional Fund (EDRF) "A way to achieve Europe".
Conflict-of-interest statement: The authors have no conflicts of interest related to this publication.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jose Tiago Silva, MD, PhD, Attending Doctor, Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”, Instituto de Investigación Hospital “12 de Octubre” (imas12), School of Medicine, Universidad Complutense, 2ª planta, bloque D. Avda. de Córdoba, s/n, Madrid 28041, Spain. j.tiago.silva@hotmail.com
Telephone: +34-91-3908000 Fax: +34-91-4695775
Received: February 20, 2019
Peer-review started: February 20, 2019
First decision: April 30, 2019
Revised: May 30, 2019
Accepted: June 7, 2019
Article in press: June 7, 2019
Published online: July 14, 2019
Processing time: 145 Days and 12.7 Hours
Abstract

Solid organ transplantation (SOT) is the best treatment option for end-stage organ disease. Newer immunosuppressive agents have reduced the incidence of graft rejection but have increased the risk of infection, particularly due to the reactivation of latent infections due to opportunistic agents such as Mycobacterium tuberculosis. Active tuberculosis (TB) after SOT is a significant cause of morbidity and mortality. Most cases of posttransplant TB are secondary to reactivation of latent tuberculosis infection (LTBI) due to the effects of long-term immunosuppressive therapy. Risk minimization strategies have been developed to diagnose LTBI and initiate treatment prior to transplantation. Isoniazid with vitamin B6 supplementation is the treatment of choice. However, liver transplantation (LT) candidates and recipients have an increased risk of isoniazid-induced liver toxicity, leading to lower treatment completion rates than in other SOT populations. Fluoroquinolones (FQs) exhibit good in vitro antimycobacterial activity and a lower risk of drug-induced liver injury than isoniazid. In the present review, we highlight the disease burden posed by posttransplant TB and summarize the emerging clinical evidence supporting the use of FQs for the treatment of LTBI in LT recipients and candidates.

Keywords: Fluoroquinolones; Mycobacterium tuberculosis; Latent tuberculosis infection; Liver transplantation; Drug-induced liver graft injury

Core tip: Active tuberculosis after solid organ transplantation, particularly after liver transplantation, has a dismal outcome. This review focuses on the burden of active tuberculosis after liver transplantation and summarizes the most recent data concerning the use of isoniazid for the treatment of latent tuberculosis infection in liver transplant recipients and candidates. In addition, we review the most relevant clinical experience in the use of fluoroquinolones as an alternative approach with a favorable safety profile for the treatment of latent tuberculosis infection in the liver transplant setting.